Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26171138
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
The Helicobacter pylori eradication in the group receiving standard -dose and
group continue taking amoxicillin for 4 weeks; a clinical trial study
#MMPMID26171138
Ehsani-Ardakani MJ
; Sedaghat M
; Eslami G
; Mohaghegh Shalmani H
Gastroenterol Hepatol Bed Bench
2015[Spr]; 8
(Suppl 1
): S54-9
PMID26171138
show ga
AIM: The aim of this study was to evaluate the Helicobacter pylori eradication in
the group receiving standard -dose twice a day for two weeks and continue taking
amoxicillin for 4 weeks. BACKGROUND: Helicobacter pylori is the major etiological
cause of chronic gastritis, gastric and duodenal ulcers, gastric cancer and
lymphoma. Therefore, patients should be treated after diagnosis of H. pylori
infection. PATIENTS AND METHODS: A total of 66 consecutive patients with rapid
urease test during endoscopy or biopsy positive for H. pylori were enrolled in
this clinical trial study during 2013-2014. Patients were divided randomly into
two groups. Group A (standard dose) received omeprazole (20 mg), amoxicillin (1
g), and clarithromycin (500 mg), all two times a day for two weeks. Group B
received standard dose like group A and in patients with H.pylori infection
amoxicillin were continued for 4 weeks. After completion of treatment, patients
did not receive any treatment for a month and then stool antigen was performed to
evaluate the H.pylori. RESULTS: The rate of successful HP eradication was
significantly higher in group A (90.9% V.s 63.6%; p=0.017). Inflation and bitter
mouth were found in 8 and 13 patients in group A and 7 and 9 patients in group B,
respectively. The incidence of adverse effects was the same (p=0.437).
CONCLUSION: Increased duration of antibiotic therapy to four weeks significantly
raises the rate of successful HP eradication with standard triple therapy without
significant increase in adverse effects.